Hot Warren Buffett Stocks To Buy For 2019

Warren Buffett stepping down from the Kraft Heinz board hasn’t “really changed anything,” Bernardo Hees, the ketchup maker’s CEO said Friday.

Hees’ comments came in response to a question from CNBC’s Becky Quick about whether Buffett’s departure would allow the company to make a hostile bid.

“I don’t think Warren leaving the board really changed anything,” Hees said, on “Squawk Box.”

“He already acknowledged he wants to decrease his travel commitments. We’re actually very lucky … he [stayed] with us for five years on the board.”

David A. Grogan | CNBC Bernardo Hees, CEO, Kraft Heinz

Kraft Heinz is backed by private equity firm 3G Capital, known for its aggressive approach to cost-cutting and dealmaking. Its business model has led analysts to speculate the food giant needs a large acquisition to find growth where it cannot create it on its own by brand building. That reputation, though, has led some to believe the company needs the ability to go hostile to get a deal done.

Hot Warren Buffett Stocks To Buy For 2019: Dr. Reddy’s Laboratories Ltd(RDY)

Advisors’ Opinion:

  • [By Keith Speights]

    The third reason behind Celgene’s low valuation is a potential threat to the biotech’s top drug Revlimid. Celgene is fighting a patent challenge over Revlimid from Dr. Reddy’s Laboratories (NYSE:RDY). The hematology drug currently generates 63% of Celgene’s total revenue. 

  • [By Lisa Levin] Companies Reporting Before The Bell
    Advance Auto Parts, Inc. (NYSE: AAP) is projected to report quarterly earnings at $1.97 per share on revenue of $2.91 billion.
    Kohl's Corporation (NYSE: KSS) is expected to report quarterly earnings at $0.5 per share on revenue of $3.95 billion.
    The TJX Companies, Inc. (NYSE: TJX) is projected to report quarterly earnings at $1.02 per share on revenue of $8.47 billion.
    AutoZone, Inc. (NYSE: AZO) is estimated to report quarterly earnings at $13.01 per share on revenue of $2.72 billion.
    Dycom Industries, Inc. (NYSE: DY) is projected to report quarterly earnings at $0.7 per share on revenue of $734.86 million.
    Eaton Vance Corp. (NYSE: EV) is estimated to report quarterly earnings at $0.79 per share on revenue of $425.42 million.
    Photronics, Inc. (NASDAQ: PLAB) is expected to report quarterly earnings at $0.07 per share on revenue of $124.17 million.
    Cracker Barrel Old Country Store, Inc. (NASDAQ: CBRL) is estimated to report quarterly earnings at $1.93 per share on revenue of $715.15 million.
    Radcom Ltd. (NASDAQ: RDCM) is expected to post quarterly earnings at $1.96 per share on revenue of $718.59 million.
    Clear Channel Outdoor Holdings, Inc. (NYSE: CCO) is projected to report quarterly earnings at $0.04 per share on revenue of $718.96 million.
    CYREN Ltd. (NASDAQ: CYRN) is estimated to report quarterly loss at $0.08 per share on revenue of $7.72 million.
    Ferroglobe PLC (NYSE: GSM) is projected to report quarterly earnings at $0.16 per share on revenue of $559.15 million.
    Dr. Reddy's Laboratories Limited (NYSE: RDY) is estimated to report earnings for its fourth quarter.
    BioLineRx Ltd. (NASDAQ: BLRX) is expected to report quarterly loss at $0.07 per share.
    Toll Brothers, Inc. (NYSE: TOL) is estimated to post quarterly earnings at $0.76 per share on revenue of $1.58 billion.

     

  • [By Shane Hupp]

    Dr.Reddy’s Laboratories (NYSE:RDY) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.

    Regenxbio (NASDAQ:RGNX) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.

  • [By Keith Speights]

    Investors’ biggest worry about Celgene is that it might not have as much time as hoped to replace the revenue that Revlimid generates: Dr. Reddy’s Laboratories (NYSE:RDY) is challenging Celgene’s patents for Revlimid.

Hot Warren Buffett Stocks To Buy For 2019: Lipocine Inc.(LPCN)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Lipocine (LPCN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Warren Buffett Stocks To Buy For 2019: ProQR Therapeutics N.V.(PRQR)

Advisors’ Opinion:

  • [By Keith Speights]

    Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) were up 16% as of 3:48 p.m. EDT on Monday. ProQR didn’t report any new announcements, but the biotech’s update last Wednesday from a phase 1/2 clinical study — of RNA medicine QR-110, in treating Leber congenital amaurosis type 10 (LCA10) — still had investors fired up.

  • [By Stephan Byrd]

    ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.15, Zacks reports.

  • [By Keith Speights]

    Three of the biggest winners were ProQR Therapeutics (NASDAQ:PRQR), MannKind Corp. (NASDAQ:MNKD), and Arrowhead Pharmaceuticals (NASDAQ:ARWR). Here’s why these biotech stocks soared this week and a look at whether they’re smart picks for investors now.

Leave a Reply

Your email address will not be published. Required fields are marked *